Welcome to the Working Group on New TB Drugs

Welcome to the Working Group on New TB Drugs

The mission of the Working Group on New TB Drugs is to ensure stakeholders in TB Drug Development from academia, government, industry, non-profit organizations, and patients themselves, are working together to facilitate and speed the development of new drugs for the treatment of tuberculosis.

About the Working Group on New TB Drugs

One of the Stop TB Partnership's seven Working Groups, the Working Group on New Drugs (WGND) is a network of experts committed to accelerating the development of effective and affordable new therapies for TB.

Read More
Why We Need New TB Drugs

Today's TB drug regimen takes too long to be effective and requires too many medications. Treatment of drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even lengthier, taking 18-24 months or longer.

Read More
The Global TB Drugs Pipeline

With the aim of increasing efficiency and coordination of the global TB drug R&D enterprise through information exchange, the WGND conducts an annual survey of the global TB drugs pipeline.

Read MoreView the Pipeline
Global Members

The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.

Total members: 132

WGND Members:

Takushi Kaneko
TB Alliance
Abubakar Yaro
Africa Health Research Organization
Jonathan Blackburn
University of Cape Town
Isabelle Cieren-Puiseux
sanofi-aventis
Christo van Niekerk
TB Alliance
Ann Ginsberg
TB Alliance
Tanya Parish
Infectious Disease Research Institute
Noroi Doi
Japan Anti-Tuberculosis Association; Research Institute of Tuberculosis
Barrington Furr
AstraZeneca
Scott Franzblau
Institute for Tuberculosis Research, University of Illinois at Chicago



> click to view all members